Search company, investor...

Alder BioPharmaceuticals

alderbio.com

Founded Year

2004

Stage

Acq - P2P | Acquired

Total Raised

$105.1M

Valuation

$0000 

Revenue

$0000 

About Alder BioPharmaceuticals

Alder BioPharmaceuticals identifies, develops and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. On October 22, 2019, Alder BioPharmaceuticals was acquired by Lundbeck.

Headquarters Location

11804 North Creek Parkway South Parkway South

Bothell, Washington, 98011,

United States

425-205-2900

Missing: Alder BioPharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alder BioPharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alder BioPharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alder BioPharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alder BioPharmaceuticals Patents

Alder BioPharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Ion channels
  • Serotonin receptor agonists
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2019

6/7/2022

G protein coupled receptors, Ion channels, Serotonin receptor agonists, Fluoroarenes, Piperidines

Grant

Application Date

2/11/2019

Grant Date

6/7/2022

Title

Related Topics

G protein coupled receptors, Ion channels, Serotonin receptor agonists, Fluoroarenes, Piperidines

Status

Grant

Latest Alder BioPharmaceuticals News

Th17 Driven Disease Treatment Market 2022 Size, Growth & Forecast Report to 2028

May 10, 2022

The latest Th17 Driven Disease Treatment Market Research Report published by Value Market Research gives in-depth analysis to show industry trends in the upcoming years. Request a FREE Sample Copy of Global Th17 Driven Disease Treatment Market Report with Full TOC At: https://www. The major players in the th17 driven disease treatment market include AbbVie, Alexion Pharmaceuticals, Alder Biopharmaceuticals, Astellas Pharma. This section covers the regional outlook, which accentuates current and future demand for the Th17 Driven Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Purchase complete Global Th17 Driven Disease Treatment Market Research Report At: https://www.

Alder BioPharmaceuticals Frequently Asked Questions (FAQ)

  • When was Alder BioPharmaceuticals founded?

    Alder BioPharmaceuticals was founded in 2004.

  • Where is Alder BioPharmaceuticals's headquarters?

    Alder BioPharmaceuticals's headquarters is located at 11804 North Creek Parkway South, Bothell.

  • What is Alder BioPharmaceuticals's latest funding round?

    Alder BioPharmaceuticals's latest funding round is Acq - P2P.

  • How much did Alder BioPharmaceuticals raise?

    Alder BioPharmaceuticals raised a total of $105.1M.

  • Who are the investors of Alder BioPharmaceuticals?

    Investors of Alder BioPharmaceuticals include H. Lundbeck, WRF Capital, Ventures West, Sevin Rosen Funds, H.I.G. BioHealth Partners and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.